文献速递前列腺癌

Ac-225-PSMA-617在Lu-177-PSMA治疗失败后的晚期mCRPC中的活性与不良事件

Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
PubMed 文献 · Eur Urol · 2020-12-05

该回顾性研究纳入26例Lu-177-PSMA治疗后进展的晚期mCRPC患者,接受Ac-225-PSMA-617治疗(中位2周期,中位活性9 MBq)。17/26例PSA下降≥50%,中位PSA-PFS 3.5个月、cPFS 4.1个月、OS 7.7个月。肝转移与更短生存相关,3/4级血液学毒性常见,口干导致部分患者停药。

要点

  • Ac-225-PSMA-617在Lu-177-PSMA失败后仍显示可测量的抗肿瘤活性。
  • 肝转移患者PSA-PFS、cPFS和OS均显著缩短。
  • 3/4级血液学毒性发生率最高达35%,口干常见且可致停药。

核心结论

  • Ac-225-PSMA-617在Lu-177-PSMA治疗失败的晚期mCRPC中显示出可测量的抗肿瘤效果。
  • 3/4级血液学副作用见于高达三分之一的患者,口干导致相关数量患者停止治疗。

研究设计与样本

  • 回顾性研究,26例患者在同情用药方案下接受Ac-225-PSMA-617治疗。
  • 入选标准包括既往阿比特龙或恩扎卢胺治疗、既往紫杉类化疗、Lu-177-PSMA治疗后进展及PSMA配体摄取阳性。
  • 既往mCRPC治疗方案中位数为6,Ac-225-PSMA-617每8周给药一次直至进展或不可耐受毒性。

主要发现

  • 共给予61周期Ac-225-PSMA-617,中位周期数2,中位活性9 MBq。
  • 17/26例患者PSA下降≥50%。
  • 中位PSA-PFS为3.5个月(95%CI 1.8-11.2),中位cPFS为4.1个月(95%CI 3-14.8),中位OS为7.7个月(95%CI 4.5-12.1)。
  • 肝转移与更短PSA-PFS(中位1.9 vs 4.0个月;p=0.02)、cPFS(中位1.8 vs 5.2个月;p=0.001)和OS(中位4.3 vs 10.4个月;p=0.01)相关。
  • 3/4级血液学毒性包括贫血(35%)、白细胞减少(27%)和血小板减少(19%);所有患者发生1/2级口干。

临床怎么用

  • 对于Lu-177-PSMA治疗失败后的晚期mCRPC,Ac-225-PSMA-617可作为可选方案,但需密切监测血液学毒性和口干。
  • 肝转移患者可能从Ac-225-PSMA-617中获益较少,需权衡治疗预期。

局限性

  • 回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Beta-emitting Lu-177-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate cancer (mCRPC), but its antitumor effect can decrease over time. OBJECTIVE: To report the safety and activity of alpha-emitting Ac-225-PSMA-617 RLT in mCRPC that has progressed after Lu-177-PSMA. DESIGN, SETTING, AND PARTICIPANTS: Twenty-six patients were treated under a compassionate use protocol. The eligibility criteria included previous treatment with abiraterone or enzalutamide, previous taxane-based chemotherapy, progression after Lu-177-PSMA, and positive PSMA-ligand uptake. The median number of previous mCRPC regimens was 6. Ac-225-PSMA-617 was given every 8 wk until progression/intolerable side effects. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prostate-specific antigen (PSA) decline, PSA progression-free survival (PSA-PFS), clinical progression-free survival (cPFS), overall survival (OS), and toxicity were measured. RESULTS AND LIMITATIONS: Sixty-one cycles of Ac-225-PSMA-617 (median number of cycles 2; median activity 9 MBq) were administered. A PSA decline of ≥50% was achieved in 17/26 patients. The median PSA-PFS, cPFS, and OS periods were 3.5 (95% confidence interval [CI] 1.8-11.2), 4.1 (95% CI 3-14.8), and 7.7 (95% CI 4.5-12.1) mo, respectively. Liver metastases were associated with shorter PSA-PFS (median 1.9 vs 4.0 mo; p = 0.02), cPFS (median 1.8 vs 5.2 mo; p = 0.001), and OS (median 4.3 vs 10.4 mo; p = 0.01). Hematological grade 3/4 toxicities were anemia (35%), leucopenia (27%), and thrombocytopenia (19%). All patients experienced grade 1/2 xerostomia. Two and six patients stopped due to hematological toxicity and xerostomia, respectively. A limitation is the retrospective design. CONCLUSIONS: Ac-225-PSMA-617 showed measurable antitumor effect after Lu-177-PSMA failure in late-stage mCRPC. Grade 3/4 hematological side effects were observed in up to one-third of patients, and xerostomia led to treatment halt in a relevant number of patients. PATIENT SUMMARY: Ac-225-labeled prostate-specific membrane antigen (PSMA)-617 therapy showed substantial antitumor effect in late metastatic castration-resistant prostate cancer after Lu-177-PSMA failure. However, dry mouth is a common side effect that caused about a quarter of patients to stop therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Feuerecker B, Tauber R, Knorr K, et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol. 2020. PMID: 33293081. doi:10.1016/j.eururo.2020.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。